Takara Bio Inc. announced that it has mutually agreed to terminate the license agreement with Tasly Biopharmaceuticals. Co. Ltd. for exclusive development, manufacturing and commercialization of oncolytic viral immunotherapy agent C- REV (canerpaturev) in the People's Republic of China. Takara Bio entered into an alliance in order to accelerate development of C-REV on May 11, 2020. Considering the global situation including the ongoing COVID-19 pandemic, Takara Bio and Tasly forethoughtfully discussed the development strategy, and then agreed to terminate the agreement after the careful consideration. Upon the effective date of termination, Tasly will return to Takara Bio all rights granted under the agreement.